Azatadine maleate/pseudoephedrine sulfate repetabs versus placebo in the treatment of severe perennial allergic rhinitis.
Sixty patients took part in a randomized double-blind comparison of azatadine/pseudoephedrine versus placebo for the treatment of severe perennial allergic rhinitis. After 2 weeks of therapy subjective patient appraisal as well as objective physician evaluation showed the active drug combination to have a beneficial effect (72% good to excellent improvement versus 40% for placebo) in reducing the signs and symptoms of this allergic disorder. No adverse reactions were reported.
D000293:Adolescent; D000328:Adult; D000368:Aged; D003533:Cyproheptadine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004338:Drug Combinations; D004809:Ephedrine / Q000627:therapeutic use*; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D006634:Histamine H1 Antagonists; D003533:Cyproheptadine; C006656:azatadine; D004809:Ephedrine